China is striving to become the global leader in biopharmaceuticals, but many of its policy steps are “innovation mercantilist” in nature. This not only is expected to threaten U.S. leadership, but also slow global life sciences innovation, with negative consequences for cures and treatments.
February 23, 2016
The United States has been the world’s medicine cabinet for too long, and it’s time for the rest of the world to stop free riding and do their share, too, writes Rob Atkinson in Forbes.
February 22, 2016
America’s success in discovering and developing drugs depends on the twin pillars of federal support for scientific research and a strong IP and reimbursement system that promotes private-sector innovation.
February 15, 2016
In testimony to the U.S. ITC, Stephen Ezell explains why biotech is a key driver of both the U.S. economy and global life sciences innovation, and he argues robust IP standards in the TPP will be critical to both.
February 2, 2016
Innovation Fact of the Week: US Leads World in Period of Data Exclusivity For Biologic Medicine Innovators
The United States leads the world in the period of data exclusivity it provides to innovators of biologic medicines, writes Adams Nager in Innovation Files.
January 28, 2016
Innovation Fact of the Week: IP Protections Spur Innovation, Contribute to Better Health Outcomes in Developing Nations
Stronger global intellectual property protection, such as the agreement on Trade-Related Aspects of Intellectual Property (TRIPS), which was signed in 1994, has helped spur innovation in health care and contributed to better health outcomes, writes John Wu in Innovation Files.
December 21, 2015
From alarmists touting an artificial intelligence apocalypse to activists fighting against genetically improved foods, this report highlights 10 of the year’s most egregious cases of neo-Luddism in action.
December 8, 2015
While many parts of the Trans-Pacific Partnership agreement will positively impact bio innovation, others will inhibit the development of the next generation of breakthrough medicines, said Stephen Ezell in testimony before the House Ways and Means Committee Democratic Members.
November 5, 2015
In comments to the White House Office of Science and Technology Policy, ITIF's Val Giddings argues there is no relationship between the degree of regulatory scrutiny a biotechnology product receives and the degree of hazard it represents.
June 22, 2015
A new paper shows that innovative treatments are adding years to cancer patients' lives.
April 16, 2015
Turkey's leaders need to create a more supportive environment for trade, investment, and innovation.